Q1 Earnings Estimate for EBS Issued By HC Wainwright

Emergent BioSolutions Inc. (NYSE:EBS) – Research analysts at HC Wainwright issued their Q1 2026 earnings per share estimates for shares of Emergent BioSolutions in a note issued to investors on Friday, March 21st. HC Wainwright analyst R. Selvaraju forecasts that the biopharmaceutical company will post earnings per share of $0.87 for the quarter. HC Wainwright currently has a “Buy” rating and a $15.00 target price on the stock. The consensus estimate for Emergent BioSolutions’ current full-year earnings is ($0.63) per share. HC Wainwright also issued estimates for Emergent BioSolutions’ Q2 2026 earnings at $1.04 EPS, Q3 2026 earnings at $1.11 EPS and Q4 2026 earnings at $0.81 EPS.

Emergent BioSolutions (NYSE:EBS) last issued its quarterly earnings results on Monday, March 3rd. The biopharmaceutical company reported $0.05 EPS for the quarter, topping analysts’ consensus estimates of ($0.35) by $0.40. Emergent BioSolutions had a negative net margin of 18.55% and a negative return on equity of 9.91%. The firm had revenue of $194.70 million for the quarter, compared to analyst estimates of $254.67 million. During the same quarter in the prior year, the firm earned ($0.77) EPS.

Separately, StockNews.com downgraded Emergent BioSolutions from a “buy” rating to a “hold” rating in a research report on Wednesday, March 5th.

Emergent BioSolutions Trading Down 4.2 %

Shares of EBS stock opened at $5.49 on Monday. The business has a 50-day moving average price of $8.33 and a two-hundred day moving average price of $8.70. Emergent BioSolutions has a 12-month low of $1.82 and a 12-month high of $15.10. The company has a quick ratio of 1.47, a current ratio of 2.88 and a debt-to-equity ratio of 1.30. The firm has a market cap of $298.31 million, a P/E ratio of -1.34 and a beta of 1.80.

Insider Activity

In other Emergent BioSolutions news, Director Neal Franklin Fowler sold 35,000 shares of the business’s stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $5.83, for a total value of $204,050.00. Following the transaction, the director now owns 101,100 shares in the company, valued at approximately $589,413. The trade was a 25.72 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 1.20% of the stock is currently owned by corporate insiders.

Institutional Trading of Emergent BioSolutions

A number of institutional investors have recently modified their holdings of the company. State Street Corp increased its holdings in Emergent BioSolutions by 864.7% during the 3rd quarter. State Street Corp now owns 1,911,327 shares of the biopharmaceutical company’s stock valued at $15,960,000 after purchasing an additional 1,713,200 shares during the period. Oak Hill Advisors LP purchased a new position in shares of Emergent BioSolutions during the third quarter valued at approximately $9,296,000. Millennium Management LLC raised its holdings in shares of Emergent BioSolutions by 83.0% during the fourth quarter. Millennium Management LLC now owns 1,481,906 shares of the biopharmaceutical company’s stock valued at $14,167,000 after acquiring an additional 671,947 shares in the last quarter. Invesco Ltd. lifted its stake in Emergent BioSolutions by 70.9% in the fourth quarter. Invesco Ltd. now owns 1,539,907 shares of the biopharmaceutical company’s stock worth $14,722,000 after acquiring an additional 638,995 shares during the period. Finally, Dimensional Fund Advisors LP boosted its holdings in Emergent BioSolutions by 67.5% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,104,058 shares of the biopharmaceutical company’s stock valued at $10,554,000 after acquiring an additional 444,790 shares in the last quarter. 78.40% of the stock is currently owned by hedge funds and other institutional investors.

Emergent BioSolutions Company Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.